1. Home
  2. NRO vs LYEL Comparison

NRO vs LYEL Comparison

Compare NRO & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Neuberger Berman Real Estate Securities Income Fund Inc.

NRO

Neuberger Berman Real Estate Securities Income Fund Inc.

N/A

Current Price

$2.70

Market Cap

186.3M

Sector

Finance

ML Signal

N/A

Logo Lyell Immunopharma Inc.

LYEL

Lyell Immunopharma Inc.

N/A

Current Price

$14.77

Market Cap

195.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
NRO
LYEL
Founded
N/A
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
186.3M
195.8M
IPO Year
2003
2021

Fundamental Metrics

Financial Performance
Metric
NRO
LYEL
Price
$2.70
$14.77
Analyst Decision
Buy
Analyst Count
0
8
Target Price
N/A
★ $38.38
AVG Volume (30 Days)
★ 234.5K
220.6K
Earning Date
01-01-0001
11-04-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $36,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$2.48
$7.20
52 Week High
$3.16
$45.00

Technical Indicators

Market Signals
Indicator
NRO
LYEL
Relative Strength Index (RSI) 59.38 75.02
Support Level $2.49 $11.87
Resistance Level $3.07 $14.97
Average True Range (ATR) 0.04 1.22
MACD 0.03 0.73
Stochastic Oscillator 78.00 77.65

Price Performance

Historical Comparison
NRO
LYEL

About NRO Neuberger Berman Real Estate Securities Income Fund Inc.

NEUBERGER BERMAN REAL ESTATE SECURITIES INCOME FUND INC is a closed-end management investment company that invests mainly in securities issued by real estate companies, including real estate investment trusts (REITs). Its primary objective is to gain high current income with capital appreciation being the second. Under normal market conditions, the Fund invests at least 90% of its total assets in income-producing common equity securities, preferred securities, convertible securities and non-convertible debt securities issued by real estate companies, including real estate investment trusts ("REITs").

About LYEL Lyell Immunopharma Inc.

Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.

Share on Social Networks: